Search
for
Sort by
Research
930-960 / 1000+ resultsresearch Catalytic Antibodies in Norm and Systemic Lupus Erythematosus
Catalytic antibodies are early indicators and active participants in the development of systemic lupus erythematosus.
research Glycyrrhetinic Acid Functionalized Nanoparticles for Drug Delivery to Liver Cancer
Licorice root-derived nanoparticles target liver cancer cells to improve treatment and reduce side effects.
research Cytotoxic Effect of YH239-EE and Its Enantiomer on MCF7 Cell Line
The (+) enantiomer of YH239-EE effectively kills breast cancer cells.
research Exploring the therapeutic potential of Selaginella doederleinii extract for cervical cancer treatment through network pharmacology and in vitro studies
Selaginella doederleinii extract shows potential for cervical cancer treatment but needs more research.
research Alopecia Universalis: Never Give Up?
Switching JAK inhibitors can lead to significant hair regrowth in severe alopecia cases.
research Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study
Healthcare claims databases can help monitor drug safety, but may report adverse events differently than direct surveillance.
research Formulation of Chitosan-Coated Brigatinib Nanospanlastics: Optimization, Characterization, Stability Assessment and In-Vitro Cytotoxicity Activity against H-1975 Cell Lines
The new Brigatinib nanocarrier is more effective against lung cancer cells than the free drug.
research Case Report: Vitiligo and Alopecia Universalis Following Rituximab Therapy in a Patient with Myasthenia Gravis
Rituximab may cause skin issues, but baricitinib can help improve them.
research An Update on the Roles of the Complement System in Autoimmune Diseases and the Therapeutic Possibilities of Anti-Complement Agents
Anti-complement agents could effectively treat autoimmune diseases with fewer side effects.
research 800 Modulating the butyrophilin-like protein 2 pathway prevents alopecia areata in C3H/HeJ mice
Modulating the BTNL2 pathway can prevent hair loss in mice.
research 532P Analyses of patient-reported outcomes (PROs) with mirvetuximab soravtansine (MIRV) versus standard chemotherapy in the randomized phase III FORWARD I study in ovarian cancer (GOG 3011)
Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.
research ACE2 and TMPRSS2 Potential Involvement in Genetic Susceptibility to SARS-COV-2 in Cancer Patients
Targeting ACE2 and TMPRSS2 may help prevent or treat COVID-19 in cancer patients.
research 0935 Unravelling the role of JAK3/TEC kinase signalling with ritlecitinib in alopecia areata lesional skin and alopecia areata-induced human hair follicles ex vivo
Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.
research Effectiveness and safety of physician–pharmacist collaborative care for rheumatoid arthritis patients: The Changi General Hospital’s experience
Collaborative care between physicians and pharmacists improved medication management for rheumatoid arthritis without raising costs.
research Population exposure–response analysis of the effect of ritlecitinib on eyebrow assessment and eyelash assessment in patients with alopecia areata
Ritlecitinib effectively regrows eyebrow and eyelash hair in alopecia areata, with 50 mg being the best dose.
research Functional analysis of vitamin D receptor (VDR) using adenovirus vector
The study found that certain mutations in the vitamin D receptor can cause rickets and potentially affect hair growth.
research Topical Delivery of Tofacitinib in Dermatology: The Promise of a Novel Therapeutic Class Using Biodegradable Dendritic Polyglycerol Sulfates
A new carrier improves skin delivery of tofacitinib for treating inflammatory skin diseases.
research A novel hairless highly immunodeficient mice model optimized for in vivo imaging
The new Hairless R/J mice model improves imaging for tumor monitoring and cancer therapy evaluation.
research Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial
Ritlecitinib effectively treats alopecia areata and is well-tolerated.
research Effective holistic characterization of small molecule effects using heterogeneous biological networks
Integrating biological networks improves drug repurposing and ADR prediction.
research Significant improvement with ivarmacitinib after suboptimal response to tofacitinib in severe alopecia areata: a case report and literature review
Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.
research Predicting therapeutic drugs for hepatocellular carcinoma based on tissue-specific pathways
Securinine and ajmaline may effectively treat liver cancer, with securinine being less toxic to normal cells.
research Ayurveda & Bioactives as Adjuvant for Dna Modulation in Cancer Treatment & Adverse Drug Reaction [ADR] – A Glimpse of Traditional Indian Nanotechnology
Ayurvedic herbs may reduce side effects and improve effectiveness of cancer treatments.
research 039 Expansion of regulatory T Cells restrains pathogenic CD8 T Cells in a murine model of alopecia areata
Expanding regulatory T cells may help treat alopecia areata by reducing harmful immune cells.
research Post SARS-CoV-2 vaccination effluvium
research Patient Profile and Treatment Characteristics of Early Ritlecitinib Initiators in the US
Ritlecitinib provides new treatment options for diverse alopecia areata patients.
research Cyproterone acetate for severe hirsutism:results of a double‐blind dose‐ranging study*
Cyproterone acetate at 2mg daily is as effective as higher doses for treating excessive hair growth in women.
research Hair Growth in a Patient with Alopecia Areata on Tocilizumab
A woman with alopecia regrew her hair after taking a higher dose of tocilizumab.
research Dupilumab in the treatment of severe atopic dermatitis refractory to systemic immunosuppression: case report
Dupilumab improved severe atopic dermatitis in a patient who didn't respond to other treatments.